Margin of Insight
← Free primer

Investment Memorandum · Preview

For informational purposes only. Not investment advice.

Aflac Incorporated

AFL

FAVORABLE

May 22, 2026

Research Conclusion

AFL at ~$103/share is a HOLD/ACCUMULATE — quality capital return compounder at approximate fair value. PWFV ~$112/share (+9%); total return ~11.5% including 2.1% dividend. The investment case is a mechanical capital return compounding story: $3B+/yr in buybacks on a declining share base generates ~7% adj. EPS CAGR. At $103 with 8.6% capital return yield and 43 consecutive dividend increases, AFL is a reliable wealth-building machine. ACCUMULATE at $88-103; BUY below $88; HOLD to $120; TRIM above $135.

Company Overview & Moat Assessment

Aflac Incorporated is the world's largest provider of supplemental insurance, offering voluntary health and life policies directly to consumers and through the worksite. It operates in two segments: Japan (~70% of earnings) with 22M+ cancer and medical insurance policies in force; and US (~30%) as the #1 worksite voluntary benefits provider. Revenue ~$17.2B FY2025. AFL's investment thesis is a capital return compounder: it earns highly predictable insurance profits and returns virtually all earnings to shareholders via buybacks ($3.5B FY2025) and 43 consecutive dividend increases. Primary risk is JPY/USD translation — ~70% of earnings in yen with depreciation from ~110 to ~151 creating a sustained ~$1.5-2.0/share EPS headwind.

▲ Bull Case

  • ◆JPY recovers to ~130: BoJ rate hikes + Fed cuts drive yen strength; each 10 JPY improvement = +$0.30-0.40/share annual adj. EPS; $1.50-2.00/share total = FY2027E adj. EPS ~$10.00; at 14x = $140/share
  • ◆Aflac Re Bermuda scales: Japan's ESR regulatory framework drives 3-5 additional whole-life coinsurance deals; capital-light earnings of $200-400M/yr within 3 years; multiple re-rating to 15-16x
  • ◆Buyback acceleration below $95: Opportunistic deployment of $4B+/yr; share count declines -7%/yr instead of -5.4%; adj. EPS CAGR accelerates to 9-10%/yr; 5-year compounding produces $12+ EPS by FY2030

▼ Bear Case

  • ◆JPY further depreciates to 165-170: Widening US-Japan rate differential; yen weakens another -10-12%; Japan earnings worth 15% less in USD; adj. EPS -$0.80-1.00/share annual; buyback pace cut to $1.5-2.0B/yr; EPS growth slows to 3-4%/yr
  • ◆Japan voluntary lapse rate acceleration: Aging in-force block + digital disruption; Japan first-year cancer insurance applications decline -5%/yr; franchise dying slowly without replacement growth
  • ◆CEO succession gap: Daniel Amos (74) exits without clear successor; Japan Post relationship is CEO-dependent; new CEO lacks institutional relationships; Japan distribution effectiveness declines; in-force persistency softens
Primary Debate on Wall Street

“The central debate: Does AFL's JPY exposure represent a temporary headwind that will normalize, or a structural permanent discount making AFL a value trap with declining Japan economics? Bull side: JPY at 151 is near historical extremes; BoJ normalization underway; AFL franchise survived every FX cycle since 1974; at 13.7x P/E, market is pricing maximum pessimism; Aflac Re is unpriced catalyst. Bear side: BoJ normalization is slow; structural Japanese fiscal dynamics keep yen weak; aging population means fewer new policy applications; AFL is a declining franchise wearing a 'capital return' mask. Consensus: 15 Buy / 10 Hold / 1 Sell; median PT ~$126 (+22%).”

Top Catalysts
  • ◆JPY/USD monthly rate movements — Yen strengthens to 140 or below (bull) vs. weakens to 160+ (bear)
  • ◆Aflac Re next deal announcement (H2 2026) — Second external reinsurance transaction signals platform viability
  • ◆Q2 2026 earnings (July 2026) — US premiums tracking +5%+ and Japan in-force stability
  • ◆Annual buyback authorization (Q4 2026) — $3B+ authorized; pace maintained
  • ◆44th consecutive dividend increase (Q4 2026) — Aristocrat streak continuation
  • ◆FY2026 proxy — CEO succession (April 2027) — Named COO/successor disclosure; governance risk resolution
Top Risks
  • ◆JPY depreciates further to 165+ (25-30% probability) — Primary earnings risk of -$0.80–1.00/share; HIGH thesis impact
  • ◆Buyback pace cut significantly (20-25% probability) — ~4% less EPS growth/yr; HIGH thesis impact; core capital return thesis at risk
  • ◆CEO Daniel Amos succession gap (15-20% probability) — Japan Post relationship is CEO-dependent; MEDIUM-HIGH thesis impact
  • ◆Japan in-force lapse acceleration >3%/yr (15-20% probability) — Japan premiums -2-4%/yr; MEDIUM thesis impact
  • ◆US supplemental market slows (10-15% probability) — US premiums flat instead of +5%/yr; LOW-MEDIUM thesis impact

Full Memo Continues

5 more sections, locked

  • ●
    Valuation Range & DCF
    Base/bull/bear fair-value range, WACC, terminal growth, sensitivity to revenue + margin assumptions.
  • ●
    Risk/Reward Assessment
    Position-sizing framework with explicit upside/downside skew and entry conditions.
  • ●
    Management & Capital Allocation
    Multi-year capital-allocation track record, incentive alignment, and management readout.
  • ●
    Monitoring Framework
    What to watch each quarter — leading indicators and inflection signals tracked by the analyst.
  • ●
    Unresolved Questions
    Open analyst questions and follow-up research items — the depth signal.

For Agents — $2 per memo

Call the JSON API with a Stripe Shared Payment Token. No account, no signup — just pay and call.

GET /api/v1/research/AFL/memo
Authorization: Bearer spt_...

Fund managers — coverage subscriptions launching soon. See marginofinsight.com.

Margin of Insight

For informational purposes only. Not investment advice.